Today is International Clinical Trials Day - a day that marks the start of the first clinical trial in 1747, and that laid the foundation for modern clinical trial research. Notably, clinical trials have played a key role in the development, efficacy and safety of many treatments and vaccines, including the mRNA vaccines used during the pandemic. To further commemorate this, the recipients of the 2022 Clinical Trials BC Awards have been announced. Congratulations to the winners!
As announced in Budget 2021, the Government of Canada is investing up to $450 million for a renewed Venture Capital Catalyst Initiative (VCCI) to increase the availability of venture capital for Canadian entrepreneurs. The renewed VCCI will allocate funding through three streams: funds-of-funds, life sciences and inclusive growth. Firms can now submit proposals. Additionally, VCCI selection committee is seeking professionals who will evaluate proposals and advise on the selection.
Sector achievements we’d like to highlight include Numinus Wellness receiving Health Canada approval to complete and provide psychedelic-assisted therapy using psilocybin to treat patients with treatment-resistant depression, and UBC’s department of Medical Genetics and School of Biomedical Engineering launching a new UBC Immunotherapeutics Research Excellence Cluster to continue building an inclusive, cross-cutting, research immunology and immune engineering community. Novateur Ventures also announced that it has participated in the $13.6M seed investment raised by Epitopea, a cancer therapeutics company recently spun out of the Université de Montréal / IRIC in partnership with IRICoR.
Nominations are open for our upcoming Life Sciences BC Awards presented by FARRIS, with an official ceremony on September 22nd, 2022 and winners being announced in the beginning of summer. These awards acknowledge and honour the efforts of individuals who are dedicated to advancing health innovations - and we encourage you to nominate a deserving candidate before June 1st, 2022.
Speaking of awards, congratulations to the BC researchers and winners of The 2022 Innovation and Translational Research Awards, and for putting new knowledge into practice to improve health care outcomes, implementing research outcomes and turning discoveries into commercial opportunities.
On June 8th, we invite you to join us for BC Showcase: BIO San Diego, a free event spotlighting some BC companies who will be attending the upcoming BIO International Convention in San Diego from June 13th-16th.
In closing, we also want to shine a spotlight on our job board, which is a fantastic resource to help aspiring individuals find a job in a growing sector and existing companies to recruit the perfect candidate.
Until next week,
Wendy and the LSBC team
|
|
|
|
LSBC's Annual Awards presented by Farris are now open for nominations.
These awards highlight groundbreaking achievements in BC's thriving sector.
Deadline: June 1, 2022.
|
|
|
|
Novateur Ventures Participates in Founding and Financing of Epitopea, a New Cancer Therapeutics Company
Novateur Ventures, a leading global life sciences advisory firm, announced it has participated in the $13.6M (£10.3M) seed investment raised by Epitopea, a cancer therapeutics company recently spun out of the Université de Montréal / IRIC in partnership with IRICoR. This investment will support the further development and application of Epitopea’s ground-breaking approaches to identify shared, aberrantly expressed tumor-specific antigens, that Epitopea has exclusively licensed... READ MORE
|
|
|
|
adMare Appoints Dr. Christine Allen as Vice-President, Ecosystem Development
adMare BioInnovations is pleased to announce the appointment of Dr. Christine Allen as Vice-President, Ecosystem Development. Dr. Allen will continue adMare’s leadership of Canada’s strong life sciences ecosystem through providing state-of-the-art infrastructure, scientific and commercial expertise, and investment capital to companies, enabling them to grow and maintain operations in Canada... READ MORE
|
|
|
|
BCIT Launches Animal Cell Culture Microcredential Starting July 18
Are you looking to expand your technical skills in the life sciences? Animal cell culture is an essential skill for many jobs in biotechnology and life sciences labs but most undergraduate programs do not offer this practical training. BCIT has 20+ years of experience providing animal cell culture training to students in the Joint UBC-BCIT Honors B.Sc. in Biotechnology program... READ MORE
|
|
|
|
Chinook Therapeutics Presents Updated Data from Bion-1301 Phase 1/2 Trial in Patients With IGA Nephropathy (IGAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (Era) Congress 2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced three mini-oral presentations on the BION-1301 and atrasentan clinical programs at the 59TH ERA Congress 2022 being held virtually and live in Paris, France... READ MORE
|
|
|
|
Embassy of Lithuania Invites to Take Part in the European Industrial Biotechnology and Bioeconomy Forum 2022 in Vilnius on 26-27 October, 2022
More than 500 industry leaders, SMEs representatives, policy makers and academia are expected in Vilnius, Lithuania to join Europe’s leading event on industrial biotechnology and the bioeconomy under the title ‘Next generation economies: Industrial biotechnology for a sustainable society’.The Forum will be hosted by the Lithuanian Biotechnology Association (LBTA) together with Go Vilnius – the city’s official business and tourism development agency... READ MORE
|
|
|
|
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-Assisted Therapy Treatment
Numinus Wellness Inc., a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced that Health Canada has approved Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression... READ MORE
|
|
|
|
Najah Sampson is Appointed President of Pfizer Canada
Najah Sampson has been named President of Pfizer Canada ULC, effective May 16, 2022. Ms. Sampson will be succeeding Cole Pinnow, who has held the position since January 2020. Mr. Pinnow has been appointed to a position within Pfizer’s global Oncology organization. We sincerely thank him for his contribution to the Canadian pharmaceutical industry and for his commitment to patients... READ MORE
|
|
|
|
Phyton Biotech Continues to Expand its Team of Scientists
Phyton Biotech, Ltd., a global leader in specialty fermentation solutions for naturally derived compounds and the largest global supplier of Paclitaxel and Docetaxel via Plant Cell Fermentation®, is delighted to announce that Dr. Marisol Ochoa-Villarreal has joined its team as a Scientist in the Company’s Research and Development Department. Ochoa-Villareal is a recognized expert in paclitaxel biosynthesis, with a specific focus on the metabolic engineering of secondary metabolites and plant tissue culture... READ MORE
|
|
|
|
New UBC Immunotherapeutics Research Excellence Cluster Launches
Once a week, Kelly McNagny sits in on meetings with medical doctors at St. Paul’s Hospital’s Centre for Heart and Lung Innovation, as they discuss their cases and their clinical research. The experience changed how Dr. McNagny, a professor and Immunologist with UBC’s department of Medical Genetics, and the School of Biomedical Engineering, sees as the best way to do basic science research... READ MORE
|
|
|
|
Boehringer Ingelheim’s Latest Investigational Treatment Slowed Lung Function Decline in People Living with Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was published in The New England Journal of Medicine (NEJM). The promising 12-week data that showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis will also be presented at the American Thoracic Society International Conference Breaking News session on May 16 in San Francisco... READ MORE
|
|
|
|
Sarclisa® (isatuximab) Combination Provides Unprecedented Median Progression Free Survival in Patients with Relapsed Multiple Myeloma Receiving a Proteasome Inhibitor Therapy
Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (Hazard Ratio HR 0.58; 95% Confidence Interval CI: 25.8 to 44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8 to 25.1; n=123), as evaluated by an Independent Review Committee... READ MORE
|
|
|
|
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announced financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” ... READ MORE
|
|
|
|
Jonathan Peacock Elected Chairman of the Board of Directors of Avantor®
The board of directors of Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries announced the election of Jonathan Peacock, 64, as chairman effective at the end of May 12's annual meeting of stockholders. Peacock, a member of Avantor’s board since 2017, succeeds Raj Gupta, 76, who announced his planned retirement earlier this year... READ MORE
|
|
|
|
BC Researchers Win Awards for Innovative Projects
Taking innovative research from concept to application is critical for improving healthcare systems and the well-being of patients. The Vancouver Coastal Health Research Institute is proud to support investigators and their ground-breaking health research with the Innovation and Translational Research Awards. This year’s recipients are putting new knowledge into practice, implementing research outcomes and turning discoveries into commercial opportunities. ..READ MORE
|
|
|
|
Venture Capital Catalyst Initiative – Call for Expressions of Interest 2022
Announced in Budget 2021 by the Government of Canada, the renewed Venture Capital Catalyst Initiative is making available up to $450 million through three new streams. These investments will build on the momentum of the Government’s previous venture capital programs, notably the Venture Capital Action Plan (Budget 2013) and the original VCCI (Budget 2017), to increase the availability of capital for Canada’s most promising firms, including targeted support for those in the life sciences sector and for entrepreneurs from traditionally underrepresented groups. ..READ MORE
|
|
Director, Corporate Communications
Gandeeva Therapeutics is a rapidly growing precision biotechnology company located in Vancouver, BC, Canada harnessing the power of cryo-EM technology and machine learning to advance drug discovery and development at scale. We are seeking an experienced Director Corporate Communications with substantial experience in developing, all aspects of a corporate communication strategy.
|
|
Research Associate
SignalChem Lifesciences Corporation is a clinical stage biotechnology company based in Richmond, British Columbia. SignalChem is seeking a well-qualified Research Associate to join the research and development team. The individual must have exceptional communication skills and perform well in a team environment.
|
|
Principal or Senior Principal Scientist, Clinical Pharmacology, Modeling
We are seeking a Principal Scientist/Senior Principal Scientist, Clinical Pharmacology, Modeling to join our team. This is a regular, full-time position. The candidate will work flexibly across a variety of projects and have expertise in pharmacokinetics and pharmacodynamics modeling particularly physiologically based PK modeling using Simcyp
|
|
IRICoR, a Centre of Excellence in Commercialization and Research specialized in drug discovery, has become a key player in the sector both nationally and internationally. IRICoR plays an increasingly pivotal role in the development of novel therapies in cancer and related areas. The mandate of this not-for-profit organization is to facilitate and accelerate the transformation of research results into innovation for the benefit of patients.
|
|
In Canada, PwC has more than 7,000 partners and staff in locations from coast to coast. With more than 110 years of excellence in Canada, they provide industry focused professional services including audit and assurance, risk assurance, tax, deals and consulting in areas such as cybersecurity and privacy, human resources, digital transformation and forensics. They help resolve complex issues and identify opportunities for public, private and government clients.
|
|
|
|
Post A Job on the LSBC Website! |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five reposts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact Megan Pan -talent@lifesciencesbc.ca
|
|
|
|
|
|
|
